Compound dossier · evidence, sources, and live market
Orforglipron
Oral GLP-1 agonist Strong evidence 0 cited studies 2 live vendors
An oral small-molecule GLP-1 receptor agonist candidate studied in metabolic research.
Evidence brief
Orforglipron is an oral, small-molecule (nonpeptide) GLP-1 receptor agonist in late-stage clinical development for type 2 diabetes and obesity; unlike injectable GLP-1 drugs it is a synthetic non-peptide taken by mouth, and most of the evidence comes from manufacturer-sponsored randomized trials.
first-party prices captured 40m ago
Newly FDA-approved: Foundayo (NDA 220934), an oral GLP-1 receptor agonist for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It has no EMA authorisation; trials continue in the EU and UK, where it remains investigational.Research use only — not medical advice.
Source: Foundayo (orforglipron) prescribing information · DailyMedchecked 2026-08-15
These figures are what pepmg still publishes about price: the floor, the middle, the spread and how many sources we track, computed from listings we captured first-party and refreshed on the same schedule as always. We no longer publish the individual listings or the sellers behind them.
Computed from 2 in-stock listings across 2 sources we captured first-party, with bulk vials, blends and statistical outliers excluded so the figures compare like with like. The spread is the highest tracked price divided by the lowest — how much the same milligram varies depending on where you look. The chart is the daily minimum; days we did not capture are left out rather than filled in.
- What the research says about orforglipron Strong evidence
Orforglipron is an oral, small-molecule (nonpeptide) GLP-1 receptor agonist in late-stage clinical development for type 2 diabetes and obesity; unlike injectable GLP-1 drugs it is a synthetic non-peptide taken by mouth, and most of the evidence comes from manufacturer-sponsored randomized trials.
Read the full review →
▸ Why compare $/mg for Orforglipron?
Prices for this compound vary widely between vendors; comparing $/mg avoids overpaying.
▸ Reading the COA
Always check each vendor's third-party Certificate of Analysis (COA) for identity and purity.
▸ Same cluster
| Retatrutide | $1.83/mg | vs Orforglipron → |
| Tirzepatide | $1.35/mg | vs Orforglipron → |
| Semaglutide | $1.22/mg | vs Orforglipron → |
| Cagrilintide | $4.60/mg | vs Orforglipron → |
| AOD-9604 | $4.00/mg | vs Orforglipron → |
| HGH Frag 176-191 | $5.73/mg | vs Orforglipron → |
| 5-Amino-1MQ | $0.92/mg | vs Orforglipron → |
| Survodutide | $7.39/mg | vs Orforglipron → |
| Mazdutide | $5.72/mg | vs Orforglipron → |
| Teduglutide | $2.37/mg | |
| Tesofensine | $159.98/mg | vs Orforglipron → |
| SLU-PP-332 | $3.33/mg | vs Orforglipron → |
| BAM15 | $1.96/mg | vs Orforglipron → |
| AICAR | $0.63/mg | vs Orforglipron → |
| Adipotide | $7.60/mg | vs Orforglipron → |
| L-Carnitine | $9.90/mg |